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Abstract
Background: Healthcare workers (HCWs) are at particular risk of acquiring pertussis and transmitting the infection to
high-risk susceptible patients and colleagues. In this paper, the return on investment (ROI) of preventively vaccinating HCWs
against pertussis to prevent nosocomial pertussis outbreaks is estimated using a hospital ward perspective, presuming an
outbreak occurs once in 10 years.
Methods: Data on the pertussis outbreak on the neonatology ward in 2004 in the Academic Medical Center
Amsterdam (The Netherlands) was used to calculate control costs and other outbreak related costs. The study
population was: neonatology ward staff members (n = 133), parents (n = 40), neonates (n = 20), and newborns
transferred to other hospitals (n = 23). ROI is presented as the amount of Euros saved in averting outbreaks by
investing one Euro in preventively vaccinating HCWs. Sensitivity analysis was performed to study the robustness
of the ROI. Results are presented at 2012 price level.
Results: Total nosocomial pertussis outbreak costs were €48,682. Direct control costs (i.e. antibiotic therapy, laboratory
investigation and outbreak management control) were €11,464. Other outbreak related costs (i.e. sick leave of HCWs;
restrictions on the neonatology ward, savings due to reduced working force required) accounted for €37,218. Vaccination
costs were estimated at €12,208. The ROI of preventively vaccinating HCWs against pertussis was 1:4, meaning 4 Euros
could be saved by every Euro invested in vaccinating HCWs to avert outbreaks. ROI was sensitive to a lower vaccine price,
considering direct control costs only, average length of stay of neonates on the neonatology ward, length of patient
uptake restrictions, assuming no reduced work force due to ward closer and presuming more than one outbreak to
occur in 10 years’ time.
Conclusion: From a hospital ward perspective, preventive vaccination of HCWs against pertussis to prevent nosocomial
pertussis outbreaks results in a positive ROI, presuming an outbreak occurs once in 10 years.
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Background
Pertussis among healthcare workers (HCWs) is of special
concern because of the potential for nosocomial exposure
to susceptible patients and other HCWs [1]. HCWs are at
particular risk of acquiring pertussis and may transmit the
infection to young infants and colleagues [2]. Compared
to the general adult population, HCWs are reported to
have an almost 1.7-times higher risk of pertussis [3]. In
literature, reports of nosocomial pertussis outbreaks fol-
lowing community or hospital exposures of HCWs are
available [4-7]. Nosocomial outbreaks not only generate a
considerable disease burden in humans, but can also result
in substantial control costs and other outbreak related
costs for hospitals. The type of expenses include diagnostic
testing, provision of antibiotic treatment or prophylaxis,
costs associated with furlough of employees, and time spent
by occupational health infection control staff to track and
identify exposed individuals, as well as costs associated with
dissemination of information [2]. Previous studies estimating
the nosocomial pertussis outbreak costs among HCWs
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concluded that these outbreaks resulted in serious adverse
health and economic consequences to the hospitals, HCWs,
patients and their families [1,5,8,9]. Using a hospital perspec-
tive, Ward et al., [5] estimated the total outbreak costs
among HCWs at €55,5791 for 91 cases in a French hospital.
Calugar et al., [1] calculated the total outbreak costs at
€76,9451,2 for 17 cases in a hospital in the Unites States.
From the hospitals’ perspective, Baggett et al., [8] calculated
costs of two hospital outbreaks in the United States at
€114,526 and €248,998 s1,2, respectively. Zivna et al., [9] esti-
mated the total outbreak costs to be €80,428 - €93,0881,2 in
a tertiary care medical center in the United States. Accord-
ing to Calugar et al., [1] cost savings and benefits can be ac-
crued by vaccinating HCWs against pertussis, with benefits
for the hospital estimated at 2.38 times a dollar invested in
vaccinating HCWs (USD 2004 estimate). Therefore, preven-
tion of nosocomial pertussis outbreaks by preventively vac-
cinating HCWs can be beneficial and has the potential to
reduce the overall disease and economic burden of pertussis.
In the Netherlands, pertussis vaccination was introduced in
1952 with long-established high vaccination coverage of 96-
97% [10]. Dutch infants are vaccinated against pertussis on
the age of 2, 3, 4, 11 months, and 4 years in the National
Immunization Program (NIP) [11], meaning in the first four
months, infants are not fully protected against pertussis and
disease occurs frequently, especially in years of high pertus-
sis circulation (i.e. every 2–4 years) [10]. A national vaccin-
ation recommendation of HCWs has yet to be made in the
Netherlands. Nosocomial pertussis outbreaks have occurred
in the Netherlands in the past decade [12,13]. However, eco-
nomic consequences of such pertussis outbreaks and the po-
tential benefits of preventively vaccinating HCWs have not
been evaluated. In this paper, we aim to calculate the return
on investment (ROI) of preventively vaccinating HCWs
against pertussis to prevent nosocomial pertussis outbreaks
in a neonatology ward using a hospital ward perspective.
Data on the nosocomial pertussis outbreak on the neonat-
ology ward in the Academic Medical Center Amsterdam
(AMC) in The Netherlands in the year 2004 (for details see
Box A.1 in Additional file 1) were used as a case study to
examine the economic impact of a pertussis outbreak in a
neonatology ward.
Methods
Data collection & study population
During the outbreak period, data were collected by the oc-
cupational health service department of the AMC (hereafter
referred as “AMC database”) on all control measures under-
taken related to newborns, their parents, staff members, and
to the organization within the hospital. The study popula-
tion consisted of: neonatology ward staff members (15 neo-
natologists, 100 nurses, 18 assistants), parents of newborns
(20 fathers, 13 lactating mothers, 7 non-lactating mothers),
neonates (20 infants) and parents of 23 newborns who were
transferred to another hospital. As data from on the pertus-
sis outbreak was used in an aggregated way without identify-
ing the individual participant, no written informed consent
and ethical approval were required from participants to per-
form the data analysis.
Assumptions
The following assumptions were made in this study as
the AMC database did not capture all data on the
outbreak:
 Due to patient uptake restrictions (i.e. for a period
of 10 days, no new patients were allowed to be
admitted on the neonatology ward), we assumed
that the following activities were performed during
regular working hours (i.e. not resulting in
additional costs for the hospital ward):
telephone calls made to parents whose children
were transferred to another hospital;
time spent by the neonatologist working on
controlling the outbreak;
survey performed by the occupational health
service department as this is normal procedure
during an outbreak in the AMC;
all drug and vaccination administrations;
PCRs done on nasopharyngeal swabs and blood
samples taken for serology;
 Based on average Dutch working population [14]
we assumed that an average working week of staff
members other than neonatologists consisted of 32
hours; neonatologists were assumed to work 42
hours/week [15];
 No further transmission of the pertussis infection
took place after restrictions on the patient uptake on
the neonatology ward were lifted;
 Reduced work force was required to run the
neonatology ward during the period of restrictions on
the patient uptake. We assumed that on day 1, 2, 3 and
4 0%, 5%, 10% and 15% reduced work force was
required, respectively. On day five and onwards, this
assumption was set at 20%.
Cost estimations
Total outbreak costs were calculated by considering:
– direct control costs (i.e. (i) medical consumption costs
containing antibiotics, (ii) laboratory investigation costs,
(iii) outbreak control management costs) and
– other outbreak related costs (i.e. (iv) replacing costs
for sick hospital staff members, (v) losses due to
restrictions on patient uptake on the neonatology
ward and (vi) savings due to a reduced work force
required on the neonatology ward during patient
uptake restriction period).
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Dutch prices were used to derive medication costs and
other resource unit costs [15-18], and where necessary up-
dated to 2012 using Dutch consumer price index (CPI) [14].
Vaccination costs were calculated by considering:
– catch-up vaccination: vaccination of all HCWs
(n = 133) one year after the outbreak based on
the list price for Infanrix® IPV (diphtheria, tetanus,
acellular pertussis and inactivated poliomyelitis)
vaccine (€34.50 per vial) [19,20];
– vaccination of newly employed HCWs staff
(assumption 10% per year) for a period of 10 years.
New HCWs were assumed to be unvaccinated but
would be vaccinated upfront when hired at 100%
coverage rate;
– booster vaccination to be provided eight years after
first vaccination due to the declining vaccine
effectiveness [21].
Return on Investment (ROI)
ROI of preventively vaccinating HCWs was calculated
by dividing the return on investment (i.e. averted out-
break costs, using the AMC outbreak costs as proxy) by
the cost of the investment (i.e. cumulative vaccination
costs including booster vaccination):
Return On Investment ¼ Averted Outbreak Costs
Vaccination Costs
 
and it is presented as a ratio: the amount of Euros saved
by averting an outbreak times one Euro invested in vac-
cinating HCWs. All costs are presented in Euro at 2012
price level and without time-discounting. Discounting is
applied in sensitivity analysis.
Model
The analysis was conducted in MS Excel, version 2007
based on the study population and the input parameters
displayed in Table 1. The outcome measures were:
 total nosocomial pertussis outbreak costs, split up as
costs of antibiotics, costs of laboratory
investigations, costs of outbreak control
management, costs due to work absence of sick staff
members, losses due to restrictions on patient
uptake and reduced costs (=savings) due to reduced
working force;
 ROI of preventively vaccinating HCW assuming one
outbreak within 10 years’ time.
Sensitivity analysis
Univariate and two-way sensitivity analysis was performed
on several input parameters to further test the robustness of
the outcomes. In Table 2, the scenarios for the sensitivity
analysis together with the values of input parameters are dis-
played. Amongst other variables, the impact of discounting
future outbreak costs and vaccination costs on the ROI was
estimated, using a discount rate of 4%, according to Dutch
health economic guidelines [15]. Also, the number of per-
tussis outbreaks in a period was varied (i.e. once or twice in
10 years, once in 20 years).
Results
Total nosocomial pertussis outbreak costs in the AMC in
the Netherlands were €48,682. Direct control cost account
for less than 25%. The majority of the costs were caused due
to patient uptake restrictions on the neonatology ward, in-
cluding savings due to reduce working force (33%), and due
to absenteeism of HCWs (43%). Medical consumption costs
were €785, laboratory investigation costs accounted for
€6,982, outbreak management control costs were €3,697,
costs due to absenteeism were €21,008, and costs due to pa-
tient uptake restrictions were €16,210). Cumulative vaccin-
ation costs, including boostering, were €12,208. The return
on investment of vaccinating HCWs was 1:4, meaning 4
Euros can be saved by investing one Euro in vaccinating
HCWs to prevent a nosocomial pertussis outbreak
(Table 3).
Sensitivity analysis
Vaccine price, inclusion of direct control costs only, average
length of stay of neonates on the neonatology ward, length
of patient uptake restrictions, assuming no reduced work
force due to ward closer, and presuming two outbreaks
would occur in 10 years time had an impact on the ROI, see
Figure 1 (for detailed information see Table A.1 in Add-
itional file 2). The ROI increased to 1:6.6 when vaccine price
was decreased to €18.30 per dose. When only direct control
costs were considered in the ratio, ROI was slightly negative
(1:-0.9). The ROI was 1:7.8 when average length of stay of
neonates in the ward was assumed to be shorter (i.e. 7 days
versus 14 days), and would be 1:2.7 if average length of stay
of neonates would be 21 days. A shorter and a prolonged
length of patient uptake restrictions resulted in a lower
(1:2.9) and a higher (1:6.9) ROI, respectively. Assuming no
reduction in the work force on the neonatology ward re-
sulted in a ROI of 1:6.5. Presuming an outbreak would occur
twice in 10 years, the ROI would be 1:7.9, if undiscounted
and 1:7.4 if discounted. All other factors, including discount-
ing, changed only slightly the calculated ROI.
Discussion
The return on investment of preventively vaccinating
HCWs against pertussis to prevent a nosocomial pertus-
sis outbreak was 1:4, meaning 4 Euros can be saved by
investing one Euro on preventive vaccination of HCWs
to prevent a pertussis outbreak. Total nosocomial per-
tussis outbreak costs in the AMC were €48,682. Direct
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Lactating mothers 13 *
Non-lactating mothers 7 *
Newborns 20 *
Parents per child 2 *
Average weight newborn (in kg) 2.2 [22]
Staff members 133 *
Medical consumption
Erythromycin cost per vial (solution of 20 mg) €0.16 [16]
Erythromycin cost per tablet €0.34 [16]
Azithromycin cost per tablet €0.53 [16]
Laboratory investigation
Number of PCRs performed:
Children 20 *
Staff members 24 *
PCR costs per unit €106.38 [18]
Number of serological tests performed:
Children 20 27 * *
Staff members
Serological test cost per unit €48.96 [23]
Outbreak control management
Crisis meetings in the hospital 5 *
Duration of a crisis meeting (in minutes) 60 *




Amount of surgical masks used during the outbreak period 24 *
Costs per unit surgical mask €1.22 [24]
Replacing sick staff members
Average working hours of nurses per week 32 [14]
Number of staff members not able to work for three days after performing the PCR test. Assumed they were all
nurses
5 *
Number of hours of nurses absence due to the PCR test 68.57 Calculated
Number of staff members absent from the neonatology ward for one week. Assumed they were all nurses. 4 *
Number of hours of nurses absence due to illness (i.e. sick leave) 160 Calculated
Restrictions patient uptake
Regular occupation of the neonatology ward, patients per day 15 *
Average length of stay of neonates in neonatology ward (in days) 14 * & Personal
communication
Average number of patients admitted on the neonatology ward per day 1,071 Calculated
Length of patient restriction uptake on the neonatology ward (in days) 10 *
Number of empty bed-days due to ward closure during the restriction period 58.93 Calculated
Cost per patient per day due to patient restriction €798.18 [23]
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control costs and other outbreak related costs were 24%
and 76% of total costs, respectively. The majority of the
costs were caused due to patient uptake restrictions on
the neonatology ward of the hospital and by absence of
the infected HCWs.
Our findings on total outbreak costs were in accordance
with Ward et al., [5] (€55,579) and Calugar et al., [1]
(€76,945). However, costs reported by Baggett et al., [8]
(€114,526 and €248,998) were much higher compared to
our study, which was primarily the result of higher
personnel costs used in Baggett et al., [8]. Our estimate of
the ROI was slightly higher than calculated by Calugar
et al., [1] but still in the same order of magnitude.
Limitations & assumptions
A major limitation of this study is the possibility of recall
bias because the data on the pertussis outbreak were
recalled from the year 2004. Another limitation is the nar-
row perspective (i.e. hospital ward) used in this study.
However, using a broader perspective and including
additional costs would have led to even a more favourable
(i.e. higher) ROI. The assumptions made in this study led
to outbreak cost estimates which can be considered as
conservative. First, handling costs of several activities (e.g.
drug and vaccination administration, PCRs, blood sam-
ples, and survey) were not considered as it was assumed
that these activities were performed by the staff themselves
during their regular working hours. Including the costs of
these activities would lead to higher total outbreak costs
and a higher ROI. Second, it was assumed that no further
transmission of the infection took place when patient up-
take restrictions on the neonatology ward were lifted. In
practice, additional infections could occur after these re-
strictions would be lifted, which would lead to additional
outbreak costs and a higher ROI. Third, additional costs
related to the spread of the infection by children who were
brought to other hospitals were beyond our perspective
(i.e. the hospital ward) and therefore not considered. But
also productivity losses due to work absence of sick parents
(i.e. only fathers as mothers would be on maternity leave)
Table 1 Study population and input parameters (all costs are expressed in 2012 Euros) (Continued)
Reduced workforce due to patient uptake restrictions
Average number of nurses & assistant working/day in the neonatology ward 30 *
Average number of consultant working/day in the neonatology ward 10 *
Average number of neonatologists working/day in the neonatology ward 6 *
Reduced working force due to ward closure:
On day 1 0% Assumed
On day 2 5%
On day 3 10%
On day 4 15%
On day 5 and onwards 20%





Infanrix IPV® costs €34.50 [20]
Staff members vaccinated 133 *
Average number of new personal in neonatology ward /year (in %) 10 Assumed
Average number of new personnel in neonatology ward /year (absolute) 13.30 Calculated
Booster vaccination after years 8 [21]
Tariff personnel
The costs for the employer are higher than the tariffs paid to the employees, we therefore multiplied the costs
per hour by
2.0 Assumed
Tariff per hour/nurses €64.78 [15]
Tariff per hour/neonatologists €155.04 [15]
Tariff per hour/others €62.54 [15]
*During the outbreak period, these data were collected by the occupational health service department of the AMC. In this paper we named this information the AMC
database.
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were disregarded because of the restricted perspective.
Both - negative externalities to the Dutch society - might
be omitted if the HCWs would have been vaccinated.
Fifth, it was assumed that vaccine uptake, both in existing
and newly joined HCWs, would be 100%, which is slightly
higher than the observed vaccine coverage in general
population (i.e. 96-97%) [10]. Also did we assume that a 8-
year booster vaccination would be sufficient to guarantee
a 100% vaccine effectiveness, which might have been an
oversimplification. Unvaccinated and or unprotected indi-
vidual HCWs, however, remain a risk of infection, and as
such a risk for a potential pertussis outbreak. Sixth,
psychological impact on parents with newborns due to a
prolonged stay and treatment in the hospital was not
quantified. Seventh, the prevented outbreak costs were
based on one single outbreak. A larger or a smaller out-
break in a slightly other setting might lead to higher or
smaller ROI than presented in the current study. Finally,
the ROI estimated in this study is based on preventing
one nosocomial pertussis outbreak. Actually, the impact
of immunization of HCWs may be much larger
as pertussis infection occurring in infants might go
unrecognized unless extensive lab diagnosis is applied.
Every 2–4 years, an extra epidemic is observed with
high number of pertussis cases in adolescents and adults
in The Netherlands [10]. However, the number of
Table 3 Return on investment of preventively vaccinating
healthcare workers against pertussis
Costs in Euros %
Direct control costs
Antibiotic therapy (a) €785 2%
Laboratory investigations (b) €6,982 14%
Outbreak control management (c) €3,697 8%
Total (a,b,c) €11,464 24%
Other outbreak related costs
Absenteeism costs (d) €21,008 43%
Restrictions on patient uptake on the ward (e) €47,036 33%2
Savings due to reduced staff costs (f )1 −/− €30,826
Total (d,e,f) €37,218 76%
Total nosocomial pertussis outbreak costs (g) €48,682 100%
Vaccination costs (h) €12,208
Ratio
Return on investment ((g-h)/h) 1:4
1Reduced work force was required due to ward closure, which led to savings in
personnel costs.
2(€47,036 + €-30,826)/€48,682 = 33%.
Table 2 Scenarios in the univariate and two-way sensitivity analysis




2 Average working days for nurses per week 3-5 −1 day and + 1 day
3 Average length of stay of neonates in neonatology ward 7-21 0.5 and 1.5 × base case
4 Length of patient restriction uptake on the neonatology ward (in days) 5-15 0.5 and 1.5 × base case
5 Average number of nurses & assistant working/day in the neonatology ward 20-40 0.5 and 1.5 × base case
6 Average number of consultant working/day in the neonatology ward 5-15 0.5 and 1.5 × base case
7 Number of staff members not able to work for 3 days after performing the PCR test 0-10 Assumed
8 Average number of new personnel in neonatology ward /year (in %) 5-15 0.5 and 1.5 × base case
9 No reduced working hours for nurses, neonatologists and
other HCW due to ward closure
0 Assumed
10 Vaccine price €18,30 [17]
11 Costs considered in the ROI - only direct control costs €11.464 Assumed
12 Undiscounted outbreak and vaccination costs with 2 outbreaks in 10 years 0% Assumed
13 Discounted outbreak and vaccination costs with 1 outbreak in 10 years 4% [15]
14 Discounted outbreak and vaccination costs with 2 outbreaks in 10 years 4% [15]
15 Undiscounted outbreak and vaccination costs with 1 outbreak in 20 years 0% Assumed
16 Discounted outbreak and vaccination costs with 1 outbreak in 20 years 4% [15]
17 Smaller neonatology ward (HCW × 0,50 and ward occupation ×0,50) 0,50 Assumed
18 Bigger neonatology ward (HCW × 1,50 and ward occupation ×1,50) 1,50 Assumed
19 Length of patient restriction uptake on the neonatology ward
(5 days) and average length of stay of neonates in neonatology ward (14 days)
5 14 Assumed
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detected nosocomial outbreaks affecting infants does
not occur at the same rate which suggests that pertussis
infection occurring in infants might go unrecognized.
As a consequence, more nosocomial outbreaks could
possibly be prevented by preventive vaccination of
HCWs, which would lead to a higher ROI. Therefore,
the results presented in this study can be considered as
conservative.
Policy implications
In the Netherlands, a national vaccination recommenda-
tion of HCWs against pertussis has yet to be made. In the
Dutch society, infants are not fully protected against per-
tussis in the first few months of their life. To provide pro-
tection to this vulnerable group, preventive vaccination of
HCWs working with vulnerable infants who are not fully
protected could be a relevant intervention. Considering
the fact that about 76% of the outbreak costs estimated in
this study were caused due to patient uptake restrictions
on the neonatology ward of the hospital and by absence of
the infected HCWs, it shows the importance of preventing
nosocomial pertussis outbreaks and their disregarded im-
pact. Also, it could be argued that hospitals as employers
should have some responsibility in preventing nosocomial
infections and protecting both, patients and staff mem-
bers. Therefore, within policy decision making on vaccin-
ation recommendations, vaccinating HCWs should also
be recommended.
Conclusion
In conclusion, the current study demonstrated that from a
hospital ward perspective, preventive vaccination of health-
care workers against pertussis to prevent nosocomial pertus-
sis outbreaks does result in a positive return on
investment (1:4). Therefore, preventive vaccination of
healthcare workers can be considered a wise use of
healthcare resources enabling the prevention of nosoco-
mial pertussis outbreaks with the tendency to reduce,
both the economic and disease burden of pertussis in
both, hospital setting and the society.
Ethics approval and consent
As data from the nosocomial pertussis outbreak in the
AMC in The Netherlands was used in an aggregated way
to model the return on investment of vaccinating health-
care workers without identifying the individual participant,
no written informed consent and ethical approval were re-
quired from participants to perform the data analysis.
Standards of reporting
As this study is not a full economic evaluation but a fi-
nancial analysis based on a mathematical model, the
Consolidated Health Economic Evaluation Reporting
Standards checklist (CHEERS) was not necessarily suit-
able to be used in this case. However, while preparing
this manuscript the attempt has been to follow where
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Only direct control costs considered in the ROI
Vaccine price
Reduced working hours for nurses, neonatologists and other HCW
Average number of nurses & assistant working/day in the neonatology ward 
Number of staff members not able to work for 3 days after performing PCR 
Average working days for nurses per week
Average number of consultant working/day in the neonatology ward




Figure 1 Tornado diagram with outcomes of the univariate and two-way sensitivity analysis.
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applicable the CHEERS guideline and to meet the
reporting standards of a scientific publication.
Data availability
All relevant raw data used in this study are presented in the
current manuscript (i.e. Tables 1, 2 and 3, Figure 1, Box A.1
in Additional file 1 and Table A.1 in Additional file 2) and
will be freely available to any scientist wishing to use them
for non-commercial purposes, without breaching participant
confidentiality.
Previous publication data
Data from this manuscript has been presented as a poster
presentation at the International Society for Pharmaco-
economoc and Outcomes Research in Amsterdam in
2014. The abstract of this poster presentation was pub-
lished in Value of Health Vol. 17, Issue 7, Page A672.
Endnotes
1Cost estimates are shown for 2012 price level using
local Consumer Price Indexes: http://stats.oecd.org/Index.
aspx?DataSetCode=MEI_PRICES#.
2Cost estimates are shown for 2012 price level using ex-
change rate from USD 2012 to EURO 2012: 0,778 (http://
stats.oecd.org/index.aspx?queryid=169).
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on the neonatology ward in the AMC in the Netherlands in 2004).
Additional file 2: Table A.1. Applied one-way and two-way sensitivity
analyses: details and results. Costs are expressed in 2012 Euros.
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